These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1035 related articles for article (PubMed ID: 7502415)

  • 1. The value of screening tests in the detection of prostate cancer. Part II: Retrospective analysis of free/total prostate-specific analysis ratio, age-specific reference ranges, and PSA density.
    Bangma CH; Kranse R; Blijenberg BG; Schröder FH
    Urology; 1995 Dec; 46(6):779-84. PubMed ID: 7502415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The value of screening tests in the detection of prostate cancer. Part I: Results of a retrospective evaluation of 1726 men.
    Bangma CH; Kranse R; Blijenberg BG; Schröder FH
    Urology; 1995 Dec; 46(6):773-8. PubMed ID: 7502414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of prostatic carcinoma: the role of TRUS, TRUS guided biopsy, digital rectal examination, PSA and PSA density.
    Men S; Cakar B; Conkbayir I; Hekimoglu B
    J Exp Clin Cancer Res; 2001 Dec; 20(4):473-80. PubMed ID: 11876539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effective prostate cancer detection. Reduction of low-yield biopsies. Investigators of the American Cancer Society National Prostate Cancer Detection Project.
    Littrup PJ; Kane RA; Mettlin CJ; Murphy GP; Lee F; Toi A; Badalament R; Babaian R
    Cancer; 1994 Dec; 74(12):3146-58. PubMed ID: 7526969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population.
    Bangma CH; Rietbergen JB; Kranse R; Blijenberg BG; Petterson K; Schröder FH
    J Urol; 1997 Jun; 157(6):2191-6. PubMed ID: 9146612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparison between 2 techniques of screening for prostatic carcinoma. Rectal exploration and transrectal ultrasonography vs. prostate specific antigen].
    Ciatto S; Bonardi R; Mazzotta A; Lombardi C; Santoni R; Cardini S; Zappa M
    Radiol Med; 1994 Oct; 88(4):453-7. PubMed ID: 7527916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Early diagnosis of prostate carcinoma with reference to the density of prostate-specific antigen].
    Schmid HP; Ravery V; Toublanc M; Boccon-Gibod L
    Schweiz Med Wochenschr; 1996 Sep; 126(36):1530-5. PubMed ID: 8927956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer.
    Schröder FH; van der Maas P; Beemsterboer P; Kruger AB; Hoedemaeker R; Rietbergen J; Kranse R
    J Natl Cancer Inst; 1998 Dec; 90(23):1817-23. PubMed ID: 9839522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective evaluation of prostate-specific antigen density and systematic biopsies for early detection of prostatic carcinoma.
    Bazinet M; Meshref AW; Trudel C; Aronson S; Péloquin F; Nachabe M; Bégin LR; Elhilali MM
    Urology; 1994 Jan; 43(1):44-51; discussion 51-2. PubMed ID: 7506853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The usefulness of prostate-specific antigen (PSA) density in patients with intermediate serum PSA level in a country with low incidence of prostate cancer.
    Yu HJ; Lai MK
    Urology; 1998 May; 51(5A Suppl):125-30. PubMed ID: 9610567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Volume-adjusted prostate-specific antigen (PSA) variables in detecting impalpable prostate cancer in men with PSA levels of 2-4 ng/mL: transabdominal measurement makes a significant contribution.
    Kobayashi T; Kawahara T; Nishizawa K; Ogura K; Mitsumori K; Ide Y
    BJU Int; 2005 Jun; 95(9):1245-8. PubMed ID: 15892809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale for using serum prostate-specific antigen (PSA) level and PSA density (PSAD) to detect prostatic malignancy in a country with low prostate cancer incidence.
    Rahardjo D; Kamil ST; Pakasi LS
    Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():563-70. PubMed ID: 10895211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does free to total ratio of prostate-specific antigen alter decision-making on prostatic biopsy?
    Alivizatos G; Deliveliotis C; Mitropoulos D; Raptides G; Louras G; Karayiannis A; Becopoulos T; Dimopoulos AM
    Urology; 1996 Dec; 48(6A Suppl):71-5. PubMed ID: 8973704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of prostate specific antigen density to improve the sensitivity of prostate specific antigen in detecting prostate carcinoma.
    Bretton PR; Evans WP; Borden JD; Castellanos RD
    Cancer; 1994 Dec; 74(11):2991-5. PubMed ID: 7525040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digitalrectal examination.
    Uzzo RG; Pinover WH; Horwitz EM; Parlanti A; Mazzoni S; Raysor S; Mirchandani I; Greenberg RE; Pollack A; Hanks GE; Watkins-Bruner D
    Urology; 2003 Apr; 61(4):754-9. PubMed ID: 12670560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Relationship between screening by stratifying cases into groups on prostate specific antigen level and the positive rate of transrectal ultrasound guided systematic sextant prostate biopsy].
    Cao XL; Gao JP; Han G; Tang J; Hong BF
    Zhonghua Wai Ke Za Zhi; 2006 Mar; 44(6):372-5. PubMed ID: 16638344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic value of percent free prostate-specific antigen: retrospective analysis of a population-based screening study with emphasis on men with PSA levels less than 3.0 ng/mL.
    Törnblom M; Norming U; Adolfsson J; Becker C; Abrahamsson PA; Lilja H; Gustafsson O
    Urology; 1999 May; 53(5):945-50. PubMed ID: 10223488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of prostate-specific antigen density after applying age-specific prostate-specific antigen reference ranges.
    Meshref AW; Bazinet M; Trudel C; Aronson S; Peloquin F; Nachabe M; Dessureault J; Aprikian AG; Begin LR; Elhilali MM
    Urology; 1995 Jun; 45(6):972-9. PubMed ID: 7539562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple vesico-urethral biopsies following radical prostatectomy: the predictive roles of TRUS, DRE, PSA and the pathological stage.
    Scattoni V; Roscigno M; Raber M; Montorsi F; Da Pozzo L; Guazzoni G; Freschi M; Rigatti P
    Eur Urol; 2003 Oct; 44(4):407-14. PubMed ID: 14499673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of free/total prostate specific antigen (f/t PSA) ratio in diagnosis of prostate carcinoma.
    Thakur V; Singh PP; Talwar M; Mukherjee U
    Dis Markers; 2003-2004; 19(6):287-92. PubMed ID: 15258330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.